AtriCure Earnings Call Transcripts
Fiscal Year 2026
-
Guidance for 2026 projects 12%-14% organic growth, led by pain management and open heart surgery innovations. New product launches, especially in pain management and appendage management, are driving adoption and ASP uplift, while clinical trials like LeAAPS and BoxX-NoAF are set to expand future opportunities.
-
A $10 billion market opportunity is being addressed through innovation in AFib and pain management, with strong global presence and rapid growth in key segments. Clinical trials and new products are set to drive further expansion, while financial performance exceeds guidance and competition is met with ongoing innovation.
Fiscal Year 2025
-
2025 saw 15% revenue growth, margin expansion, and strong cash generation, led by pain management and open ablation. 2026 guidance projects 12–14% growth, with continued innovation, positive cash flow, and margin improvement, despite competitive and reimbursement headwinds.
-
Flex Mini's rapid adoption and higher ASP drove strong Q3 growth, while Encompass and Box No AF trials are expanding clinical impact. Pain management is growing with cryoSPHERE MAX and XT, and financials show robust EBITDA and margin expansion, targeting mid-teens revenue growth.
-
Significant growth is expected through product innovation, clinical trials, and market expansion, with strong financial performance and operational leverage. New product launches and clinical evidence are set to double the addressable market and drive margin improvement.
-
Strong Q3 results were driven by new product launches and robust growth in core franchises, with significant runway remaining in open ablation, appendage management, and pain management. Innovation and clinical trials are expected to expand the addressable market, while financial discipline supports margin expansion and sustained growth.
-
Third quarter revenue grew 15.8% year-over-year to $134.3 million, with strong gains in appendage management, open ablation, and pain management. Adjusted EBITDA and cash generation exceeded expectations, prompting raised full-year guidance and continued investment in innovation and clinical trials.
-
Growth accelerated in Q2, driven by new product launches and strong adoption, with innovation and clinical trials expected to expand the addressable market to $10B by 2030. Leadership is maintained through continuous product improvement and robust clinical evidence.
-
Strong internal innovation and clinical evidence are driving double-digit growth, with new products like cryoSPHERE MAX and AtriClip FLEX-Mini boosting both volume and profitability. Open appendage management is expanding rapidly, while hybrid and minimally invasive segments face headwinds.
-
Q2 2025 revenue rose 17% year-over-year to $136.1M, with strong growth in appendage management and pain management. Adjusted EBITDA more than doubled, and 2025 guidance was raised for both revenue and profitability, despite ongoing hybrid therapy pressures.
-
The conference highlighted strong growth across business segments, ongoing innovation, and a focus on profitability. PFA adoption is reshaping the AFib market, but durable solutions and new product launches are driving expansion. Long-term strategy targets $1B revenue by 2030.
-
Q1 2025 saw 14% revenue growth, strong gains in pain and appendage management, and a 200%+ increase in adjusted EBITDA. Guidance for 2025 was reiterated with raised EBITDA expectations, while new product launches and clinical trial progress are set to drive multi-year growth.
-
A robust innovation pipeline, major clinical trials, and expanding reimbursement are driving growth in large, underpenetrated markets. Financial targets include $1B revenue and 20%+ EBITDA margin by 2030, with hybrid therapies and new pain management products supporting long-term expansion.
-
Targeting over $10 billion in underpenetrated markets, the business achieved 17% growth in 2024 and expects $517–$527 million in 2025 sales with strong EBITDA gains. Innovation, clinical evidence, and new product launches are driving expansion, with pain management and international markets leading growth.
Fiscal Year 2024
-
2024 saw 17% revenue growth to $465M, driven by strong Pain Management and Open Ablation performance, with adjusted EBITDA rising to $31M. 2025 guidance projects 11–13% revenue growth and nearly 40% higher adjusted EBITDA, led by new product launches and international expansion.
-
Integration of new PFA technology with RF devices is underway, with first-in-human trials expected next year. The Clip franchise is growing despite competition, supported by new product launches and strong clinical evidence. Financial performance is improving, with continued R&D investment and a focus on core business execution.
-
Strong growth was driven by product innovation, international expansion, and robust U.S. performance, with new launches like FLEX-Mini and cryoSPHERE+ enhancing margins. Market competition and PFA adoption are expanding the patient funnel, while ongoing clinical trials and reimbursement changes support long-term growth.
-
Strong Q3 growth was driven by new product launches and robust open ablation performance, with further gains expected from full-year effects of recent innovations and international expansion. Competitive pressures persist in MIS, but differentiated technology and strategic investments support long-term growth and profitability.
-
Q3 2024 saw 18% revenue growth, strong adjusted EBITDA, and positive cash flow, driven by robust demand across pain management, open ablation, and appendage management. Full-year guidance was raised, with continued innovation and new product launches supporting future growth.
-
Large, under-penetrated markets and strong product innovation are driving consistent mid-teens growth, with new launches like FLEX Mini and cryoSPHERE MAX expected to boost volumes and pricing. Despite short-term distractions from new technologies and competitors, robust clinical evidence and expanding international presence support a positive long-term outlook.
-
Q2 2024 revenue grew 15% year-over-year to $116.3 million, with strong gains in pain management, open ablation, and international markets. Guidance for 2024 was revised to $456–$461 million due to temporary softness in MIS segments from PFA competition, but profitability and cash flow remain strong.